Business Wire

WA-AMAZON.COM-INC

Share
Amazon Secures Up to 83 Launches from Arianespace, Blue Origin, and United Launch Alliance for Project Kuiper

Amazon (NASDAQ: AMZN) today announced agreements with Arianespace, Blue Origin, and United Launch Alliance (ULA) to provide heavy-lift launch services for Project Kuiper, Amazon’s initiative to increase global broadband access using a constellation of satellites in low Earth orbit (LEO). The contracts total up to 83 launches over a five-year period, providing capacity for Amazon to deploy the majority of its 3,236-satellite constellation. It is the largest commercial procurement of launch vehicles in history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005519/en/

“Project Kuiper will provide fast, affordable broadband to tens of millions of customers in unserved and underserved communities around the world,” said Dave Limp, Senior Vice President for Amazon Devices & Services. “We still have lots of work ahead, but the team has continued to hit milestone after milestone across every aspect of our satellite system. These launch agreements reflect our incredible commitment and belief in Project Kuiper, and we’re proud to be working with such an impressive lineup of partners to deliver on our mission.”

Project Kuiper aims to provide high-speed, low-latency broadband to a wide range of customers, including individual households, schools, hospitals, businesses, government agencies, disaster relief operations, mobile operators, and other organizations working in places without reliable internet connectivity. Amazon is designing and developing the entire system in-house, combining a constellation of advanced LEO satellites with small, affordable customer terminals and a secure, resilient ground-based communications network. Project Kuiper will leverage Amazon’s global logistics and operations footprint, as well as Amazon Web Services’ (AWS) networking and infrastructure, to serve a diverse, global customer base. Project Kuiper will also apply Amazon’s experience producing low-cost devices and services like Echo and Kindle to deliver service at an affordable, accessible price for customers.

“Securing launch capacity from multiple providers has been a key part of our strategy from day one,” said Rajeev Badyal, Vice President of Technology for Project Kuiper at Amazon. “This approach reduces risk associated with launch vehicle stand-downs and supports competitive long-term pricing for Amazon, producing cost savings that we can pass on to our customers. These large, heavy-lift rockets also mean we can deploy more of our constellation with fewer launches, helping simplify our launch and deployment schedule. We’re excited to move one step closer to connecting residential, business, and government customers around the world.”

The scale of these contracts will also boost the wider launch services industry, driving innovation and job creation in the United States and Europe. Suppliers from 49 U.S. states help develop and manufacture the next-generation, heavy-lift launch vehicles from Blue Origin and ULA, while Arianespace relies on ArianeGroup’s network of suppliers from 13 European countries to produce its Ariane 6 rocket. In addition, Amazon is working with Beyond Gravity (formerly RUAG Space), a Switzerland-headquartered space technology provider, to build low-cost, scalable satellite dispensers that will help deploy the Project Kuiper constellation. Beyond Gravity is opening an all-new production facility as a result of the partnership, doubling its production capacity and creating dozens of jobs in Linköping, Sweden.

Arianespace

Arianespace, the European spaceline, has established itself as a leader in the global launch services industry, completing 15 successful launches last year, including the launch of the James Webb Space Telescope in late December. Arianespace is on its way to start operating its next-generation heavy-lift launch vehicle, Ariane 6, which is scheduled to launch for the first time by the end of this year. Amazon has secured 18 Ariane 6 rockets as part of this initial agreement.

“This contract, the largest we’ve ever signed, is a great moment in Arianespace’s history. We are honored to be given a significant role to play in the deployment of Amazon’s Project Kuiper, which aims to connect tens of millions of people to the internet,” said Stéphane Israël, CEO of Arianespace. “It will build on the European innovative spirit, industrial might, and years of experience, and it is a major win for the European launcher industry. That Amazon has chosen the Ariane 6 to do the job is a matter of tremendous pride for us and a great vote of confidence in our new launch vehicle.”

Blue Origin

Amazon has signed an agreement with Blue Origin to secure 12 launches using New Glenn, with options for up to 15 additional launches. New Glenn is powered by seven BE-4 engines and its reusable first stage is built for a minimum of 25 missions.

“We’re honored to support Amazon’s ambitious mission to provide reliable, affordable broadband to unserved and underserved communities around the world through New Glenn and our BE-4 engines,” said Jarrett Jones, Senior Vice President, New Glenn, Blue Origin. “New Glenn’s seven-meter fairing offers unprecedented mass and volume capabilities, providing Project Kuiper maximum launch flexibility. We also congratulate our partner, United Launch Alliance. We’re proud to build American-made engines for ULA’s Vulcan Centaur.”

United Launch Alliance

Amazon’s agreement with ULA covers 38 launches on Vulcan Centaur, ULA’s newest heavy-lift launch vehicle. This launch services contract also covers production and launch infrastructure to support a higher cadence of launches at Cape Canaveral Space Force Station, including a new, dedicated version of the Vulcan Launch Platform (VLP). ULA is making additional investments in its Spaceflight Processing & Operations Center (SPOC) to deliver a second ULA facility capable of full vehicle processing, transforming the launch site to have two parallel “launch lanes” for high-cadence operations. The agreement is in addition to Project Kuiper’s existing deal to secure nine Atlas V vehicles from ULA.

“This agreement marks the beginning of an exciting new era for ULA and for the entire U.S. launch industry. With a total of 47 launches between our Atlas and Vulcan vehicles, we are proud to launch the majority of this important constellation,” said Tory Bruno, ULA’s president and CEO. “It will support hundreds of jobs, especially in places like Alabama, Colorado and Florida, and Amazon’s investments in launch infrastructure and capability upgrades will benefit both commercial and government customers.”

Project Kuiper plans to launch two prototype missions later this year on ABL Space Systems’ RS1 rocket. There are now more than 1,000 people at Amazon working on Project Kuiper, and the team continues to make progress as it approaches a full, production-ready deployment—finalizing its high-performance satellite design, producing a compact, affordable customer terminal, and deploying a secure, reliable communications network that connects satellites to customers and infrastructure on the ground. Once deployed, the Kuiper System will have the capacity to serve tens of millions of residential, business, and government customers in places without reliable broadband. Moving forward, Amazon will continue to partner with companies that share its commitment to closing the global digital divide and creating new opportunities for innovation. To learn more about Project Kuiper, watch our overview video .

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding anticipated business activities, made in this press release are forward-looking. We use words such as aims, anticipates, believes, expects, future, intends, will, and similar expressions to identify forward-looking statements. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Actual results and outcomes could differ materially for a variety of reasons, including, among others, changes in our liquidity, financial condition, or capital allocation and financing strategies or in the debt and equity markets, including as a result of fluctuations in foreign exchange rates, changes in global economic conditions and customer spending, world events, the rate of growth of the Internet, online commerce, and cloud services, the amount that Amazon.com invests in new business opportunities and the timing of those investments, the mix of products and services sold to customers, the mix of net sales derived from products as compared with services, the extent to which we owe income or other taxes, competition, management of growth, potential fluctuations in operating results, international growth and expansion, the outcomes of claims, litigation, government investigations, and other proceedings, fulfillment, sortation, delivery, and data center optimization, risks of inventory management, variability in demand, the degree to which we enter into, maintain, and develop commercial agreements, proposed and completed acquisitions and strategic transactions, payments risks, and risks of fulfillment throughput and productivity. In addition, the global economic climate and additional or unforeseen effects from the global pandemic amplify many of these risks. These risks and uncertainties, as well as other risks and uncertainties that could cause our actual results to differ significantly from management’s expectations, are described in greater detail in Amazon.com’s filings with the Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K and subsequent filings. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, you are advised to consult any additional disclosures we make in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye